Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 27 of 27 publications.

Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005 Dec 1;99(3):689-95.

Tennis P, Sherrill B, Fernandez C, Dolan C. Cancer risk in asthmatic populations. Ann Allergy Asthma Immunol. 2005 Nov 30;95(4):354-60.

Wolowacz SE, Roskell NS, Christie A, Kerr G, Cameron D. The cost of hospital care for relapsed breast cancer in the UK based on a large patient-level resource utilisation dataset. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy.

Wolowacz SE, Roskell NS, Christie A, Kerr G, Cameron D. Per-patient cost of hospital care for advanced breast cancer in the UK based on a large patient-level resource utilisation dataset. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A42.

Abetz L, Coombs JH, Keininger DL, Earle CC, Wade C, Bury-Maynard D, Copley-Merriman K, Hsu MA. Development of the cancer chemotherapy satisfaction questionnaire (CCSQ): item generation and content validity testing. Value Health. 2005 Nov;8(Suppl 1):S41-53.

Hoyo C, Berchuck A, Halabi S, Bentley RC, Moorman P, Calingaert B, Schildkraut JM. Anthropometric measurements and epithelial ovarian cancer risk in african–american and white women. Cancer Causes Control. 2005 Oct 1;16(8):955-63.

Kaye JA, Jick H. Antibiotics and the risk of breast cancer. Epidemiology. 2005 Sep;16(5):688-90.

White RH, Chew HK, Zhou H, Parikh-Patel A, Harris DH, Harvey D, Wun T. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. JAMA. 2005 Aug 8;165(15):1782-7.

Mines DI, Novelli LA, Yu H. Lymphoma risk in patients with rheumatoid arthritis who received 2 or more disease modifying anti-rheumatic drugs (DMARDs): a retrospective cohort study in the GPRD. Poster presented at the 21st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2005. Nashville, TN. [abstract] Pharmacoepidemiol Drug Saf. 2005 Aug; 14(S2):S30.

Gutierrez LP, Maguire A, Mattsson A, Wilton P. Incidence of malignant neoplasm in children treated with recombinant growth hormone: the KIGS registry experience 1987-1994. Poster presented at the 21st International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2005. Nashville, TN. [abstract] Pharmacoepidemiol Drug Saf. 2005 Aug; 14(S1):S330.

Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol. 2005 Aug;174(2):753-6.

Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Berchuck A. Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol. 2005 Jul 1;193(1):75-82.

Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005 Jun 1;23(16):3668-75.

Irish W, Sherrill B, Cole B, Gard C, Glendenning GA, Mouridsen H. Quality-Adjusted Survival in a Crossover Trial of Letrozole Versus Tamoxifen in Postmenopausal Women with Advanced Breast Cancer. Ann Oncol. 2005 May 18;16(9):1458-62.

Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR, Murphy S, Berchuck A. Transforming growth factorbeta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecol Oncol. 2005 May 1;97(2):543-9.

Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005 May 1;23(13):2946-54.

Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Validation of the Functional assessment of cancer therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat. 2005 Apr 1;90(3):295-8.

Moorman PG, Berchuck A, Calingaert B, Halabi S, Schildkraut JM. Antidepressant medication use for and risk of ovarian cancer. Obstet Gynecol. 2005 Apr 1;105(4):725-30.

Midkiff KD. The endpoint verification internal computerized tracking system for the national lung screening trial. Poster presented at the Endpoint Verification Committee Meeting; April 2005.

Midkiff KD. The endpoint verification process (death review) for the national lung screening trial. Poster presented at the Bi-Annual Meeting of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Steering Committee; April 2005. Bethesda, MD.

Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen-treated breast cancer patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer. 2005 Mar 15;103(6):1114-21.

Yost KJ, Sorenson MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health. 2005 Mar;8(2):117-27.

Monk BJ, Wang J, Im S, Stock RJ, Peters, 3rd WA, Liu PY, Barrett, 2nd RJ, Berek JS, Souhami L, Grigsby PW, Gordon W,Jr, Alberts DS, Gynecologic Oncology Group, Southwest Oncology Group, Radiation Therapy Oncology Group. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol. 2005 Mar;96(3):721-8.

Phillips KA, Haas J, Hiatt RA, Kerlikowske K, Ladabaum U, Liang S, Nagamine M, Potter M, Van Bebber S, Walsh J, Johnson FR, Marshall D, Marshall J, Kulin N, Thabane L, Ramsey S, Veenstra D. The SCREEN study: an integrated approach to increasing colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2005 Jan 1;14(2):549.

Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Y. Relationship between dcis grade to phenotypic cytokeratin markers. Poster presented at the 94th Annual Meeting of the United States and Canadian Academy of Pathology; 2005.

Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q. The relationship between the expression of cytokeratin cell origin markers and er, pr, her-2/neu, and egfr in high grade and non-high grade dcis. Poster presented at the 96th Annual Meeting of the American Association for Cancer Research; 2005.

Im SS, Gordon AN, Buttin BM, Leath CA3rd, Gostout BS, Shah C, Hatch KD, Wang J, Berman ML. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol. 2005 Jan;105(1):35-41.